Skip to main content
SpringerLink
Log in

Drug Treatment of Body Image Disturbance in Mental Disorders

  • Chapter
  • First Online:
Body Image, Eating, and Weight

  • 2197 Accesses

Abstract

No drug has an approved indication for eating disorders and body dysmorphic disorder with the exception of fluoxetine for bulimia nervosa (BN) and lisdexamfetamine for binge eating disorder (BED). This chapter reviews the studies which explicitly reported body image disturbance or body image dissatisfaction as primary or secondary measures of outcome. The clinical target of ameliorating body image disturbance with drugs may be realistically reached in BN and body dysmorphic disorder (BDD), while is less convincing in anorexia nervosa (AN), where drugs are hardly useful, and in BED. The model of BDD may suggest that higher dosages of selective serotonin reuptake inhibitors (SSRI) than those usually recommended may be helpful. In any case, we know that body image disturbance is particularly resistant to therapy, and thus it can probably be faced with a combined treatment where psychotherapy has an essential role.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Halmi KA, Eckert E, LaDu TJ, Cohen J. Anorexia nervosa. Treatment efficacy of cyproheptadine and amitriptyline. Arch Gen Psychiatry. 1986;43:177–81.

    Article  CAS  Google Scholar 

  2. Lacey JH, Crisp AH. Hunger, food intake and weight: the impact of clomipramine on a refeeding anorexia nervosa population. Postgrad Med J. 1980;56(Suppl 1):79–85.

    PubMed  Google Scholar 

  3. Gwirtsman HE, Guze BH, Yager J, Gainsley B. Fluoxetine treatment of anorexia nervosa: an open clinical trial. J Clin Psychiatry. 1990;51:378–82.

    CAS  PubMed  Google Scholar 

  4. Attia E, Haiman C, Walsh BT, Flater SR. Does fluoxetine augment the inpatient treatment of anorexia nervosa? Am J Psychiatry. 1998;155:548–51.

    Article  CAS  Google Scholar 

  5. Barbarich NC, McConaha CW, Gaskill J, La Via M, Frank GK, Achenbach S, et al. An opentrial of olanzapine in anorexia nervosa. J Clin Psychiatry. 2004;65:1480–2.

    Article  CAS  Google Scholar 

  6. Kaye WH, Nagata T, Weltzin TE, Hsu LK, Sokol MS, McConaha C, et al. Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa. Biol Psychiatry. 2001;49:644–52.

    Article  CAS  Google Scholar 

  7. Walsh BT, Kaplan AS, Attia E, Olmsted M, Parides M, Carter JC, et al. Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. JAMA. 2006;295:2605–12.

    CAS  PubMed  Google Scholar 

  8. Bergh C, Eriksson M, Lindberg G, Södersten P. Selective serotonin reuptake inhibitors in anorexia. Lancet. 1996;348(9039):1459–60.

    Article  CAS  Google Scholar 

  9. Fassino S, Leombruni P, Daga G, Brustolin A, Migliaretti G, Cavallo F, Rovera G. Efficacy of citalopram in anorexia nervosa: a pilot study. Eur Neuropsychopharmacol. 2002;12:453–9.

    Article  CAS  Google Scholar 

  10. Santonastaso P, Friederici S, Favaro A. Sertraline in the treatment of restricting anorexia nervosa: an open controlled trial. J Child Adolesc Psychopharmacol. 2001;11:143–50.

    Article  CAS  Google Scholar 

  11. Safer DL, Darcy AM, Lock J. Use of mirtazapine in an adult with refractory anorexia nervosa and comorbid depression: a case report. Int J Eat Disord. 2011;44:178–81.

    PubMed  Google Scholar 

  12. Safer DL, Arnow KD. Suprathreshold duloxetine for treatment-resistant depression, anorexia nervosa binge-purging type, and obsessive-compulsive disorder: a case report. Innov Clin Neurosci. 2012;9(3):13–6.

    PubMed  PubMed Central  Google Scholar 

  13. Cassano GB, Miniati M, Pini S, Rotondo A, Banti S, Borri C, et al. Six-month open trial of haloperidol as an adjunctive treatment for anorexia nervosa: a preliminary report. Int J Eat Disord. 2003;33:172–7.

    Article  Google Scholar 

  14. Mauri M, Miniati M, Mariani MG, Ciberti A, Dell’Osso L. Haloperidol for severe anorexia nervosa restricting type with delusional body image disturbance: a nine-case chart review. Eat Weight Disord. 2013;18(3):329–32.

    Article  Google Scholar 

  15. Ruggiero GM, Laini V, Mauri MC, Ferrari VM, Clemente A, Lugo F, Mantero M, Redaelli G, Zappulli D, Cavagnini F. A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics. Prog Neuro-Psychopharmacol Biol Psychiatry. 2001;25:1049–59.

    Article  CAS  Google Scholar 

  16. Kishi T, Kafantaris V, Sunday S, Sheridan EM, Correll CU. Are antipsychotics effective for the treatment of anorexia nervosa? Results from a systematic review and meta-analysis. J Clin Psychiatry. 2012;73(6):e757–66.

    Article  CAS  Google Scholar 

  17. Balestrieri M, Oriani MG, Simoncini A, Bellantuono C. Psychotropic drug treatment in anorexia nervosa. Search for differences in efficacy/tolerability between adolescent and mixed-age population. Eur Eat Disord Rev. 2013;21(5):361–73.

    Article  Google Scholar 

  18. Miniati M, Mauri M, Ciberti A, Mariani MG, Marazziti D, Dell’Osso L. Psychopharmacological options for adult patients with anorexia nervosa. CNS Spectr. 2016;21(2):134–42.

    Article  Google Scholar 

  19. Lebow J, Sim LA, Erwin PJ, Murad MH. The effect of atypical antipsychotic medications in individuals with anorexia nervosa: a systematic review and meta-analysis. Int J Eat Disord. 2013;46(4):332–9.

    Article  Google Scholar 

  20. Bosanac P, Kurlender S, Norman T, Hallam K, Wesnes K, Manktelow T, Burrows G. An open-label study of quetiapine in anorexia nervosa. Hum Psychopharmacol. 2007;22:223–30.

    Article  CAS  Google Scholar 

  21. Powers PS, Klabunde M, Kaye W. Double-blind placebo-controlled trial of quetiapine in anorexia nervosa. Eur Eat Disord Rev. 2012;20(4):331–4.

    Article  Google Scholar 

  22. Court A, Mulder C, Kerr M, Yuen HP, Boasman M, Goldstone S, Fleming J, Weigall S, Derham H, Huang C, McGorry P, Berger G. Investigating the effectiveness, safety and tolerability of quetiapine in the treatment of anorexia nervosa in young people: a pilot study. J Psychiatr Res. 2010;44:1027–34.

    Article  Google Scholar 

  23. Trunko ME, Schwartz TA, Duvvuri V, Kaye WH. Aripiprazole in anorexia nervosa and low-weight bulimia nervosa: case reports. Int J Eat Disord. 2011;44(3):269–75.

    Article  Google Scholar 

  24. Aigner M, Treasure J, Kaye W, Kasper S, WFSBP Task Force On Eating Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. World J Biol Psychiatry. 2011;12(6):400–43.

    Article  Google Scholar 

  25. McElroy SL, Guerdjikova AI, Mori N, Keck PE Jr. Psychopharmacologic treatment of eating disorders: emerging findings. Curr Psychiatry Rep. 2015;17(5):35.

    Article  Google Scholar 

  26. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.

    Book  Google Scholar 

  27. Cooper PJ, Taylor MJ, Cooper Z, Fairburn CG. The development and validation of the body shape questionnaire. Int J Eat Disord. 1987;6:485–94.

    Article  Google Scholar 

  28. Mondraty N, Birmingham CL, Touyz S, Sundakov V, Chapman L, Beumont P. Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa. Australas Psychiatry. 2005;13:72–5.

    Article  Google Scholar 

  29. Brambilla F, Garcia CS, Fassino S, Daga GA, Favaro A, Santonastaso P. Olanzapine therapy in anorexia nervosa: psychobiological effects. Int Clin Psychopharmacol. 2007;22:197–204.

    Article  Google Scholar 

  30. Attia E, Kaplan AS, Walsh BT, Gershkovich M, Yilmaz Y, Musante D, et al. Olanzapine versus placebo for out-patients with anorexia nervosa. Psychol Med. 2011;41(10):2177–82.

    Article  CAS  Google Scholar 

  31. Kafantaris V, Leigh E, Hertz S, Berest A, Schebendach J, Sterling WM, et al. A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol. 2011;21(3):207–12.

    Article  CAS  Google Scholar 

  32. Hagman J, Gralla J, Sigel E, Ellert S, Dodge M, Gardner R, et al. A double-blind, placebo-controlled study of risperidone for the treatment of adoles- cents and young adults with anorexia nervosa: a pilot study. J Am Acad Child Adolesc Psychiatry. 2011;50(9):915–24.

    Article  Google Scholar 

  33. Gardner RM, Boice R. A computer program for measuring body size distortion and body dissatisfaction. Behav Res Methods Instrum Comput. 2004;36(1):89–95.

    Article  Google Scholar 

  34. Wooley OW, Roll S. The Color-A-Person Body Dissatisfaction Test: stability, internal consistency, validity, and factor structure. J Pers Assess. 1991;56(3):395–413.

    Article  CAS  Google Scholar 

  35. Misra M, Katzman DK, Estella NM, Eddy KT, Weigel T, Goldstein MA, Miller KK, Klibanski A. Impact of physiologic estrogen replacement on anxiety symptoms, body shape perception, and eating attitudes in adolescent girls with anorexia nervosa: data from a randomized controlled trial. J Clin Psychiatry. 2013;74(8):e765–71.

    Article  Google Scholar 

  36. Barlow J, Blouin J, Blouin A, Perez E. Treatment of bulimia with desipramine: a double-blind crossover study. Can J Psychiatry. 1988;33:129–33.

    Article  CAS  Google Scholar 

  37. Leitenberg H, Rosen JC, Wolf J, Vara LS, Detzer MJ, Srebenik D. Comparison of cognitive-behaviour therapy and desipramine in the treatment of builimia nervosa. Behav Res Ther. 1994;32:37–45.

    Article  CAS  Google Scholar 

  38. Fichter MM, Leibl K, Rief W, Brunner E, Schmidt-Auberger S, Engel RR. Fluoxetine versus placebo: a double blind study with bulimic in patients undergoing intensive psychotherapy. Pharmacopsychiatry. 1991;24:1–7.

    Article  CAS  Google Scholar 

  39. Goldbloom DS, Olmsted M, Davis R, Clewes J, Heinmaa M, Rockert W, Shaw B. A randomised controlled trial of fluoxetine and cognitive behavioural therapy for bulimia nervosa: short-term outcome. Behav Res Ther. 1997;35:803–11.

    Article  CAS  Google Scholar 

  40. Brambilla F, Draisci A, Peirone A, Brunetta M. Combined cognitive-behavioral, psychopharmacological and nutritional therapy in bulimia nervosa. Neuropsychobiology. 1995;32:68–71.

    Article  CAS  Google Scholar 

  41. Carruba MO, Cuzzolaro M, Riva L, Bosello O, Liberti S, Castra R, et al. Efficacy and tolerability of moclobemide in bulimia nervosa: a placebo-controlled trial. Int Clin Psychopharmacol. 2001;16:27–32.

    Article  CAS  Google Scholar 

  42. Blouin AG, Blouin JH, Perez EL, Bushnik T, Zuro C, Mulder E. Treatment of bulimia with fenfluramine and desipramine. J Clin Psychopharmacol. 1988;8(4):261–9.

    Article  CAS  Google Scholar 

  43. Leombruni P, Amianto F, Delsedime N, Gramaglia C, Abbate-Daga G, Fassino S. Citalopram versus fluoxetine for the treatment of patients with bulimia nervosa: a single-blind randomized controlled trial. Adv Ther. 2006;23:481–94.

    Article  CAS  Google Scholar 

  44. Fassino S, Amianto F, Gramaglia C, Facchini F, Abbate Daga G. Temperament and character in eating disorders: ten years of studies. Eat Weight Disord. 2004;9(2):81–90.

    Article  CAS  Google Scholar 

  45. Fichter MM, Krüger R, Rief W, Holland R, Döhne J. Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating-specefic psychopathology. J Clin Psychopharmacol. 1996;16:9–18.

    Article  CAS  Google Scholar 

  46. Hedges DW, Reimherr FW, Hoopes SP, Rosenthal NR, Kamin M, Karim R, Capece JA. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo- controlled trial, part 2: improvement in psychiatric measures. J Clin Psychiatry. 2003;64(12):1449–54.

    Article  CAS  Google Scholar 

  47. Marcus MD, Wing RR, Ewing L, Kern E, McDermott M, Gooding W. A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters. Am J Psychiatry. 1990;147:876–81.

    Article  CAS  Google Scholar 

  48. Ricca V, Mannucci E, Mezzani B, Moretti S, Di Bernardo M, Bertelli M, et al. Fluoxetine and fluvoxamine combined with individual cognitive-behaviour therapy in binge eating disorder: a one-year follow-up study. Psychother Psychosom. 2001;70:298–306.

    Article  CAS  Google Scholar 

  49. Golay A, Laurent-Jaccard A, Habicht F, Gachoud JP, Chabloz M, Kammer A, et al. Effect of orlistat in obese patients with binge eating disorder. Obes Res. 2005;13:1701–8.

    Article  CAS  Google Scholar 

  50. Buhlmann U, Glaesmer H, Mewes R, Fama JM, Wilhelm S, Brähler E. Updates on the prevalence of body dysmorphic disorder: a population-based survey. Psychiatry Res. 2010;178(1):171–5.

    Article  Google Scholar 

  51. Hartmann AS, Greenberg JL, Wilhelm S. The relationship between anorexia nervosa and body dysmorphic disorder. Clin Psychol Rev. 2013;33(5):675–85.

    Article  Google Scholar 

  52. Hollander E, Wong CM. Body dysmorphic disorder, pathological gambling, and sexual compulsions. J Clin Psychiatry. 1995;56(Suppl 4):7–12.

    PubMed  Google Scholar 

  53. Jolanta JRJ, Tomasz MS. The links between body dysmorphic disorder and eating disorders. Eur Psychiatry. 2000;15:302–5.

    Article  Google Scholar 

  54. Phillips KA, Kaye WH. The relationship of body dysmorphic disorder and eating disorders to obsessive-compulsive disorder. CNS Spectr. 2007;12(5):347–58.

    Article  Google Scholar 

  55. Phillips KA, Hollander E. Treating body dysmorphic disorder with medication: evidence, misconceptions, and a suggested approach. Body Image. 2008;5(1):13–27.

    Article  Google Scholar 

  56. Mancuso SG, Knoesen NP, Castle DJ. Delusional versus nondelusional body dysmorphic disorder. Compr Psychiatry. 2010;51(2):177–82.

    Article  Google Scholar 

  57. Phillips KA, Hollander E, Rasmussen SA, Aronowitz BR, DeCaria C, Goodman WK. A severity rating scale for body dysmorphic disorder: development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale. Psychopharmacol Bull. 1997;33(1):17–22.

    CAS  PubMed  Google Scholar 

  58. Rosen JC, Reiter J. Development of the body dysmorphic disorder examination. Behav Res Ther. 1996;34(9):755–66.

    Article  CAS  Google Scholar 

  59. Hollander E, Allen A, Kwon J, Aronowitz B, Schmeidler J, Wong C, et al. Clomipramine vs desipramine crossover trial in body dysmorphic disorder: Selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry. 1999;56(11):1033–9.

    Article  CAS  Google Scholar 

  60. Phillips KA, Albertini RS, Rasmussen SA. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry. 2002;59(4):381–8.

    Article  CAS  Google Scholar 

  61. Phillips KA, Najjar F. An open-label study of citalopram in body dysmorphic disorder. J Clin Psychiatry. 2003;64(6):715–20.

    Article  CAS  Google Scholar 

  62. Phillips KA. An open-label study of escitalopram in body dysmorphic disorder. Int Clin Psychopharmacol. 2006;21(3):177–9.

    Article  Google Scholar 

  63. Perugi G, Giannotti D, Di Vaio S, Frare F, Saettoni M, Cassano GB. Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia). Int Clin Psychopharmacol. 1996;11(4):247–54.

    Article  CAS  Google Scholar 

  64. Phillips KA, Dwight MM, McElroy SL. Efficacy and safety of fluvoxamine in body dysmorphic disorder. J Clin Psychiatry. 1998;59(4):165–71.

    Article  CAS  Google Scholar 

  65. Allen A, Hadley SJ, Kaplan A, Simeon D, Friedberg J, Priday L, Baker BR, Greenberg JL, Hollander E. An open-label trial of venlafaxine in body dysmorphic disorder. CNS Spectr. 2008;13(2):138–44.

    Article  Google Scholar 

  66. Ipser JC, Sander C, Stein DJ. Pharmacotherapy and psychotherapy for body dysmorphic disorder. Cochrane Database Syst Rev. 2009;1:CD005332.

    Google Scholar 

  67. Fang A, Matheny NL, Wilhelm S. Body dysmorphic disorder. Psychiatr Clin North Am. 2014;37(3):287–300.

    Article  Google Scholar 

  68. Phillips KA, Albertini RS, Siniscalchi JM, Khan A, Robinson M. Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study. J Clin Psychiatry. 2001;62(9):721–7.

    Article  CAS  Google Scholar 

  69. Phillips KA. Olanzapine augmentation of fluoxetine in body dysmorphic dis-order. Am J Psychiatry. 2005;162(5):1022–3.

    Article  Google Scholar 

  70. Phillips KA. Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatry. 2005;162(2):377–9.

    Article  Google Scholar 

  71. Nakaaki S, Murata Y, Furukawa TA. Efficacy of olanzapine augmentation of paroxetine therapy in patients with severe body dysmorphic disorder. Psychiatry Clin Neurosci. 2008;62(3):370.

    Article  Google Scholar 

  72. Uzun O, Ozdemir B. Aripiprazole as an augmentation agent in treatment-resistant body dysmorphic disorder. Clin Drug Investig. 2010;30(10):707–10.

    Article  Google Scholar 

  73. Loréa N, Van Wijnendaele R. Body dysmorphic disorder and psychosis. Case reports and discussion. Encéphale. 2012;38(1):37–41.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. DAME, University of Udine, Udine, Italy

    Matteo Balestrieri

Authors
  1. Matteo Balestrieri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matteo Balestrieri .

Editor information

Editors and Affiliations

  1. Formerly University Sapienza of Rome, Editor-in-Chief of Eating and Weight Disorders, Campiglia Marittima (LI), Italy

    Massimo Cuzzolaro

  2. Department of Neuroscience, University of Turin, Torino, Italy

    Secondo Fassino

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Balestrieri, M. (2018). Drug Treatment of Body Image Disturbance in Mental Disorders. In: Cuzzolaro, M., Fassino, S. (eds) Body Image, Eating, and Weight. Springer, Cham. https://doi.org/10.1007/978-3-319-90817-5_26

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-90817-5_26

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-90816-8

  • Online ISBN: 978-3-319-90817-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation